Rallybio Corporation (RLYB)

NASDAQ: RLYB · IEX Real-Time Price · USD
5.55
-0.43 (-7.19%)
Nov 29, 2022 3:59 PM EDT - Market closed
-7.19%
Market Cap 221.81M
Revenue (ttm) n/a
Net Income (ttm) -62.87M
Shares Out 30.78M
EPS (ttm) -1.75
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 58,703
Open 5.98
Previous Close 5.98
Day's Range 5.54 - 6.12
52-Week Range 4.86 - 15.89
Beta n/a
Analysts Buy
Price Target 31.11 (+460.5%)
Earnings Date Nov 9, 2022

About RLYB

Rallybio Corporation, a clinical-stage biotechnology company, engages in discovering, developing, manufacturing, and delivering therapies that enhance the lives of patients suffering from severe and rare diseases. Its lead product candidate is RLYB212, a monoclonal anti-HPA-1a antibody that is in Phase I clinical trial for the prevention of fetal and neonatal alloimmune thrombocytopenia (FNAIT). The company is also developing RLYB211, a polyclonal anti-HPA-1a antibody that is in a Phase 1/2 clinical trial for the prevention of FNAIT; RLYB114, a... [Read more]

Industry Biotechnology
IPO Date Jul 29, 2021
Employees 44
Stock Exchange NASDAQ
Ticker Symbol RLYB
Full Company Profile

Financial Performance

Financial Statements

Analyst Forecast

According to 11 analysts, the average rating for RLYB stock is "Buy." The 12-month stock price forecast is 31.11, which is an increase of 460.54% from the latest price.

Price Target
$31.11
(460.54% upside)
Analyst Consensus: Buy
Stock Forecasts

News

Rallybio to Present at Upcoming Investor Conferences in November

NEW HAVEN, Conn.--( BUSINESS WIRE )--Rallybio Corporation (Nasdaq: RLYB), a clinical-stage biotechnology company committed to identifying and accelerating the development of life-transforming therapies ...

2 weeks ago - Business Wire

Rallybio Announces Pricing of $50 Million Public Offering

NEW HAVEN, Conn.--( BUSINESS WIRE )--Rallybio Corporation (“Rallybio”) (Nasdaq: RLYB) today announced the pricing of an underwritten public offering of 5,000,001 shares of its common stock at a price to...

2 weeks ago - Business Wire

Rallybio Announces Proposed Public Offering

NEW HAVEN, Conn.

2 weeks ago - Business Wire

Rallybio Reports Third Quarter 2022 Financial Results

NEW HAVEN, Conn.

3 weeks ago - Business Wire

Rallybio Announces Positive Preliminary Results for RLYB212, an anti-HPA-1a Monoclonal Antibody for the Prevention of...

NEW HAVEN, Conn.--(BUSINESS WIRE)--Rallybio Corporation (Nasdaq: RLYB) today announced positive preliminary results from its ongoing Phase 1b proof-of-concept study of RLYB212, an anti-HPA-1a monoclonal...

2 months ago - Business Wire

Rallybio to Present at the 2022 Wells Fargo Healthcare Conference

NEW HAVEN, Conn.--(BUSINESS WIRE)--Rallybio Corporation (Nasdaq: RLYB), a clinical-stage biotechnology company committed to identifying and accelerating the development of life-transforming therapies fo...

2 months ago - Business Wire

Rallybio Reports Second Quarter 2022 Financial Results

NEW HAVEN, Conn.--(BUSINESS WIRE)--Rallybio Corporation (Nasdaq: RLYB), a clinical-stage biotechnology company committed to identifying and accelerating the development of life-transforming therapies fo...

3 months ago - Business Wire

Rallybio Appoints Wendy K. Chung, M.D.

NEW HAVEN, Conn.--(BUSINESS WIRE)--Rallybio Corporation (Nasdaq: RLYB), a clinical-stage biotechnology company committed to identifying and accelerating the development of life-transforming therapies fo...

3 months ago - Business Wire

Rallybio Announces Retirement of Jeffrey Fryer, CPA, Chief Financial Officer

NEW HAVEN, Conn.--(BUSINESS WIRE)--Rallybio Corporation (Nasdaq: RLYB), a clinical-stage biotechnology company committed to identifying and accelerating the development of life-transforming therapies fo...

5 months ago - Business Wire

Rallybio to Present at Upcoming Investor Conferences in June

NEW HAVEN, Conn.--(BUSINESS WIRE)--Rallybio Corporation (Nasdaq: RLYB), a clinical-stage biotechnology company committed to identifying and accelerating the development of life-transforming therapies fo...

5 months ago - Business Wire

Rallybio Reports First Quarter 2022 Financial Results

NEW HAVEN, Conn.--(BUSINESS WIRE)--Rallybio Corporation (Nasdaq: RLYB), a clinical-stage biotechnology company committed to identifying and accelerating the development of life-transforming therapies fo...

6 months ago - Business Wire

Rallybio Announces In-Licensing of Potential First-In-Class Preclinical Antibody Candidate from Sanofi

NEW HAVEN, Conn.--(BUSINESS WIRE)--Rallybio Corporation (Nasdaq: RLYB), a clinical-stage biotechnology company committed to identifying and accelerating the development of life-transforming therapies fo...

6 months ago - Business Wire

Rallybio Appoints Christine A. Nash and Hui Liu, Ph.D.

NEW HAVEN, Conn.--(BUSINESS WIRE)--Rallybio Corporation (Nasdaq: RLYB), a clinical-stage biotechnology company committed to identifying and accelerating the development of life-transforming therapies fo...

7 months ago - Business Wire

Rallybio Reports Fourth Quarter and Full Year 2021 Financial Results

NEW HAVEN, Conn.--(BUSINESS WIRE)--Rallybio Corporation (Nasdaq: RLYB), a clinical-stage biotechnology company committed to identifying and accelerating the development of life-transforming therapies fo...

8 months ago - Business Wire

Rallybio to Present at the Cowen 42nd Annual Health Care Conference

NEW HAVEN, Conn.--(BUSINESS WIRE)--Rallybio Corporation (Nasdaq: RLYB), a clinical-stage biotechnology company committed to identifying and accelerating the development of life-transforming therapies fo...

9 months ago - Business Wire

Ami Bavishi Joins Rallybio to Lead Investor Relations and Corporate Communications

NEW HAVEN, Conn.--(BUSINESS WIRE)--Rallybio Corporation (Nasdaq: RLYB), a clinical-stage biotechnology company committed to identifying and accelerating the development of life-transforming therapies fo...

10 months ago - Business Wire

Rallybio Highlights Portfolio Advances and Outlines Expected Upcoming Milestones for 2022

NEW HAVEN, Conn.--(BUSINESS WIRE)--Rallybio Corporation (Nasdaq: RLYB), a clinical-stage biotechnology company committed to identifying and accelerating the development of life-transforming therapies fo...

10 months ago - Business Wire

Rallybio (RLYB) Sees Hammer Chart Pattern: Time to Buy?

Rallybio (RLYB) has been struggling lately, but the selling pressure may be coming to an end soon.

10 months ago - Zacks Investment Research

Rallybio Reports Positive Data in Its Clinical Program for the Prevention of Fetal and Neonatal Alloimmune Thrombocyt...

NEW HAVEN, Conn.--(BUSINESS WIRE)--Rallybio Corporation (Nasdaq: RLYB), a clinical-stage biotechnology company committed to identifying and accelerating the development of life-transforming therapies fo...

11 months ago - Business Wire

Rallybio Corporation to Present at the 4th Annual Evercore ISI HealthCONx Conference

NEW HAVEN, Conn.--(BUSINESS WIRE)--Rallybio Corporation (Nasdaq: RLYB), a clinical-stage biotechnology company committed to identifying and accelerating the development of life-transforming therapies fo...

1 year ago - Business Wire

Rallybio to Present at the Jefferies London Healthcare Conference

NEW HAVEN, Conn.--(BUSINESS WIRE)--Rallybio Corporation (Nasdaq: RLYB), a clinical-stage biotechnology company committed to identifying and accelerating the development of life-transforming therapies fo...

1 year ago - Business Wire

Rallybio Corporation Reports Third Quarter 2021 Financial Results and Recent Business Highlights

NEW HAVEN, Conn.--(BUSINESS WIRE)--Rallybio Corporation (Nasdaq: RLYB), a clinical-stage biotechnology company committed to identifying and accelerating the development of life-transforming therapies fo...

1 year ago - Business Wire

Rallybio Corporation Reports Second Quarter 2021 Financial Results and Recent Business Highlights

NEW HAVEN, Conn.--(BUSINESS WIRE)---- $RLYB #FNAIT--Rallybio Corporation (Nasdaq: RLYB), a clinical-stage biotechnology company committed to identifying and accelerating the development of life-transfor...

1 year ago - Business Wire

Andreas Halvorsen Gets a Healthy Dose of Rallybio

Viking Global leader Andreas Halvorsen (Trades, Portfolio) disclosed a stake in Rallybio Corp. ( RLYB , Financial) earlier this week, seeing a value opportunity in a newly public company.

1 year ago - GuruFocus